Ribociclib

Small molecule

Also known as LEE011

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Early breast cancer Kisqali in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence (see section 5.1 for selection criteria). In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or metastatic breast cancer Kisqali is indicated for the treatment of women with HR-positive, HER2-negative locally advanced or...
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (26)
Breast Cancer
NCT07237256 · UNICANCER
2025-12-18 – 2037-12-31 · Breast Cancer
What this study did
NCT07400523 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-02-10 – 2031-02-10 · Breast Cancer
What this study did
NCT05827081 · Novartis Pharmaceuticals
2024-02-28 – 2030-09-20 · Early Breast Cancer
What this study did
NCT07391774 · National Cancer Institute (NCI)
2026-08-10 – 2029-07-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
What this study did
NCT03081234 · Novartis Pharmaceuticals
2018-03-31 – 2025-11-17 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07085767 · Olema Pharmaceuticals, Inc.
2025-11-03 – 2032-01 · Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT04862663 · AstraZeneca
2021-05-10 – 2029-08-14 · Locally Advanced (Inoperable) or Metastatic Breast Cancer
What this study did
NCT07647328 · AstraZeneca
2026-06-15 – 2029-02-28 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT06065748 · Hoffmann-La Roche
2023-12-11 – 2029-02-12 · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
What this study did
NCT04964934 · AstraZeneca
2021-06-30 – 2028-09-01 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT06377852 · American Society of Clinical Oncology
2024-10-29 – 2028-09-01 · Metastatic Breast Cancer
What this study did
NCT04055493 · Women's Cancer Study Group GmbH
2019-07-02 – 2027-07-31 · Breast Cancer Female
What this study did
NCT05207709 · SOLTI Breast Cancer Research Group
2022-03-28 – 2026-03-26 · Metastatic Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03462251 · iOMEDICO AG
2018-05-24 – 2022-11-30 · Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
What this study did
NCT03905343 · Swiss Cancer Institute
2019-06-25 – 2021-04-15 · Breast Cancer
What this study did
NCT03096847 · Novartis Pharmaceuticals
2016-10-24 – 2020-02-06 · Advanced Metastatic Breast Cancer
What this study did
NCT03050398 · Novartis Pharmaceuticals
2017-06-07 – 2019-03-08 · Breast Cancer
What this study did
Phase 2 (50)
Breast Cancer
NCT05900206 · Karolinska University Hospital
2023-10-26 – 2032-04-30 · Breast Cancer
What this study did
NCT05296746 · SOLTI Breast Cancer Research Group
2022-05-03 – 2031-12-01 · Breast Cancer Stage II
What this study did
NCT07380646 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-01-07 – 2028-06-01 · Leucogen, Ribociclib, Neutropenia (Low White Blood Cell Count), Breast Cancer
What this study did
NCT06481956 · Zheng Yabing
2023-10-25 – 2027-10-10 · HER2-positive Advanced Breast Cancer
What this study did
NCT03283384 · Borstkanker Onderzoek Groep
2019-06-15 – 2027-08 · Breast Neoplasms
What this study did
NCT02712723 · Qamar Khan
2016-02 – 2026-12 · Breast Cancer
What this study did
NCT03285412 · Massachusetts General Hospital
2017-12-12 – 2026-10 · Breast Cancer
What this study did
NCT03078751 · Novartis Pharmaceuticals
2017-06-20 – 2020-03-09 · Breast Cancer
What this study did
NCT03248427 · SOLTI Breast Cancer Research Group
2017-07-13 – 2019-07-20 · Breast Cancer
What this study did
NCT01919229 · Novartis Pharmaceuticals
2013-10 – 2014-09 · Early Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07423611 · Fudan University
2026-10-01 – 2030-12-31 · Breast Cancer
What this study did
NCT06953882 · Yale University
2025-07-09 – 2030-09 · HER2 Negative Breast Cancer
What this study did
NCT05467891 · Oana Danciu
2022-09-13 – 2029-08-15 · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06062498 · Northwestern University
2023-09-29 – 2029-07-01 · Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
What this study did
NCT05816655 · Korea University Guro Hospital
2023-05-31 – 2029-06-30 · Metastatic Breast Cancer
What this study did
NCT07195227 · MedSIR
2026-03-24 – 2028-03 · Hormon Receptor Positive Breast Cancer, Breast Cancer
What this study did
NCT07054190 · Hoffmann-La Roche
2025-09-09 – 2027-09-28 · Breast Cancer
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT06375707 · The First Affiliated Hospital with Nanjing Medical University
2024-01-09 – 2026-05-30 · Advanced Breast Cancer
What this study did
NCT06656624 · The First Affiliated Hospital with Nanjing Medical University
2024-08-13 – 2025-12-31 · Advanced Breast Cancer
What this study did
NCT03944434 · Fondazione Sandro Pitigliani
2018-12-27 – 2025-11-27 · Breast Cancer
What this study did
NCT03671330 · Novartis Pharmaceuticals
2018-08-29 – 2025-05-09 · Breast Cancer
What this study did
NCT03822468 · Novartis Pharmaceuticals
2019-06-11 – 2024-08-30 · Breast Cancer
What this study did
NCT05163106 · University Hospital, Akershus
2022-12-01 – 2024-07-30 · Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer, Luminal A Breast Cancer, Luminal B Breast Cancer
What this study did
NCT02035813 · Prof. Wolfgang Janni
2014-01 – 2024-01-10 · HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
What this study did
NCT04256941 · M.D. Anderson Cancer Center
2019-05-31 – 2023-09-22 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03477396 · City of Hope Medical Center
2018-06-14 – 2023-06-05 · Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03555877 · GBG Forschungs GmbH
2018-03-15 – 2022-07-21 · Breast Cancer Metastatic
What this study did
NCT02632045 · Melissa K Accordino
2016-03 – 2022-01-04 · Metastatic Breast Cancer, Breast Carcinoma
What this study did
NCT02657928 · Mayo Clinic
2016-07-08 – 2020-10-07 · Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma
What this study did
Other / comorbidity
NCT05843253 · Nationwide Children's Hospital
2024-08-22 – 2034-08-28 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
What this study did
NCT03008408 · M.D. Anderson Cancer Center
2017-08-18 – 2028-08-31 · Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT04116541 · Centre Leon Berard
2020-01-28 – 2027-10 · Malignant Solid Tumor
What this study did
NCT04417621 · Novartis Pharmaceuticals
2020-10-30 – 2027-02-02 · Melanoma
What this study did
NCT02934568 · Novartis Pharmaceuticals
2016-12-15 – 2027-02-01 · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
What this study did
NCT03673124 · Gynecologic Oncology Group
2019-05-20 – 2026-12-31 · Low Grade Serous Carcinoma
What this study did
NCT03114527 · Fox Chase Cancer Center
2017-08-08 – 2026-12 · Soft Tissue Sarcoma
What this study did
NCT03070301 · Memorial Sloan Kettering Cancer Center
2017-02-27 – 2024-01-31 · Neuroendocrine Tumors
What this study did
NCT02159066 · Pfizer
2014-07-23 – 2023-01-10 · Melanoma
What this study did
NCT03484923 · Novartis Pharmaceuticals
2018-09-10 – 2022-12-30 · Melanoma
What this study did
NCT02524119 · University of Texas Southwestern Medical Center
2016-04 – 2020-09 · Hepatocellular Carcinoma
What this study did
NCT03096912 · Assaf-Harofeh Medical Center
2016-07 – 2020-04 · Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma
What this study did
NCT02420691 · M.D. Anderson Cancer Center
2015-08-25 – 2019-06-05 · Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Nonfunctional Pancreatic Neuroendocrine Tumor, Thymus Neoplasm
What this study did
NCT02300987 · Novartis Pharmaceuticals
2015-02-26 – 2018-02-21 · Teratoma
What this study did
NCT02187783 · Novartis Pharmaceuticals
2014-08-25 – 2018-01-17 · Tumors With CDK4/6 Pathway Activation
What this study did
NCT02571829 · Hadassah Medical Organization
2016-05 – 2017-10 · Liposarcoma, Soft Tissue Sarcoma
What this study did
Phase 1/2 (27)
Breast Cancer
NCT05319873 · Jonsson Comprehensive Cancer Center
2022-04-07 – 2028-04-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03090165 · Kari Wisinski
2018-05-07 – 2026-10 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT07164976 · Nagoya City University
2025-10-01 – 2030-04-01 · Breast Cancer
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04802759 · Hoffmann-La Roche
2021-06-22 – 2029-05-30 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
What this study did
NCT05563220 · Stemline Therapeutics, Inc.
2023-01-24 – 2028-12-28 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07002177 · Forward Pharmaceuticals Co., Ltd.
2025-06-01 – 2028-11-01 · Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
What this study did
NCT06726148 · Novartis Pharmaceuticals
2025-04-03 – 2028-09-25 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
What this study did
NCT06188520 · AstraZeneca
2023-12-05 – 2027-06-30 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
What this study did
NCT01872260 · Novartis Pharmaceuticals
2013-10-22 – 2027-02-26 · Breast Cancer
What this study did
NCT03913234 · Yonsei University
2019-06-10 – 2023-10-30 · HER2-positive Breast Cancer, Postmenopausal, Metastatic Breast Cancer
What this study did
NCT02732119 · Novartis Pharmaceuticals
2016-06-14 – 2020-02-25 · Breast Cancer
What this study did
Other / comorbidity
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
NCT07767474 · Antares Therapeutics, Inc
2026-08-31 – 2030-01-31 · Advanced Solid Tumors
What this study did
NCT05358249 · Novartis Pharmaceuticals
2022-10-24 – 2026-09-28 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
What this study did
NCT02555189 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2015-12-01 – 2023-09-01 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
What this study did
NCT01543698 · Pfizer
2012-05-28 – 2023-03-09 · Solid Tumors Harboring a BRAF V600 Mutation
What this study did
NCT02494921 · Rahul Aggarwal
2015-11-20 – 2021-07-30 · Prostate Cancer
What this study did
NCT02985125 · Georgetown University
2017-05-04 – 2020-09-28 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT02607124 · Children's Hospital Medical Center, Cincinnati
2016-04 – 2018-08 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
What this study did
NCT01781572 · Pfizer
2013-06 – 2018-02-20 · Locally Advanced or Metastatic NRAS Mutant Melanoma
What this study did
NCT01777776 · Array BioPharma
2013-07 – 2015-04 · Locally Advanced Metastatic BRAF Mutant Melanoma
What this study did
Phase 1 (53)
HR+/HER2- Metastatic Breast Cancer
NCT05870579 · Novartis Pharmaceuticals
2023-11-13 – 2032-05-27 · Breast Cancer
What this study did
NCT05996107 · University of Michigan Rogel Cancer Center
2024-02-27 – 2030-02 · Breast Cancer
What this study did
NCT06625775 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2024-10-29 – 2028-11 · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
What this study did
NCT05508906 · Olema Pharmaceuticals, Inc.
2022-08-31 – 2028-01-31 · Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05683418 · Totus Medicines
2023-02-15 – 2027-12 · HR+/HER2-negative Breast Cancer
What this study did
NCT06239467 · OnKure, Inc.
2024-02-26 – 2027-08-01 · Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
What this study did
NCT03616587 · AstraZeneca
2018-10-11 – 2027-06-24 · ER+ HER2- Advanced Breast Cancer
What this study did
NCT05216432 · Relay Therapeutics, Inc.
2021-12-08 – 2027-04-30 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
What this study did
NCT02608216 · University of Pennsylvania
2015-11 – 2026-11 · Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
What this study did
NCT04315233 · University of Utah
2021-05-03 – 2025-09-25 · Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
What this study did
NCT05252416 · Blueprint Medicines Corporation
2022-04-07 – 2025-07-04 · Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
What this study did
NCT05759949 · Relay Therapeutics, Inc.
2023-03-29 – 2025-04-11 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
What this study did
NCT05384119 · Tvardi Therapeutics, Incorporated
2023-01-09 – 2024-05-06 · Breast Cancer
What this study did
NCT02754011 · UNICANCER
2017-02-02 – 2022-12-23 · Breast Cancer
What this study did
NCT02586675 · H. Lee Moffitt Cancer Center and Research Institute
2016-02-23 – 2021-10-27 · Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
What this study did
NCT04585724 · Emory University
2020-06-12 – 2021-09-13 · Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT02734615 · Novartis Pharmaceuticals
2016-06-14 – 2021-09-13 · Advanced or Metastatic ER+ Breast Cancer
What this study did
NCT03294694 · Dana-Farber Cancer Institute
2017-11-08 – 2020-10-14 · Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
What this study did
NCT01857193 · Novartis Pharmaceuticals
2013-09-06 – 2020-04-16 · Breast Cancer
What this study did
NCT02599363 · Abramson Cancer Center at Penn Medicine
2016-01 – 2019-03-12 · Advanced Breast Cancer
What this study did
NCT02088684 · Novartis Pharmaceuticals
2014-05-19 – 2018-04-17 · Breast Cancer
What this study did
NCT02154776 · Novartis Pharmaceuticals
2014-06-27 – 2016-10-26 · Advanced or Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT05238922 · Incyte Corporation
2022-07-05 – 2027-08-31 · Solid Tumors
What this study did
NCT03333343 · Novartis Pharmaceuticals
2018-01-29 – 2027-07-12 · EGFR-mutant Non-small Cell Lung Cancer
What this study did
NCT03740334 · Dana-Farber Cancer Institute
2019-01-30 – 2027-04-30 · Acute Lymphoblastic Leukemia ALL
What this study did
NCT02933736 · Nader Sanai
2016-10-17 – 2027-03 · Glioblastoma Multiforme, Meningioma
What this study did
NCT06959979 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2024-11-25 – 2027-02-28 · Medulloblastoma, Childhood
What this study did
NCT04213404 · National Taiwan University Hospital
2020-03-13 – 2025-01 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT03434262 · St. Jude Children's Research Hospital
2018-03-05 – 2024-05-24 · Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
What this study did
NCT02974725 · Novartis Pharmaceuticals
2017-02-24 – 2024-04-24 · Non-Small Cell Lung Cancer, Melanoma
What this study did
NCT04000529 · Novartis Pharmaceuticals
2019-07-30 – 2024-01-15 · Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
What this study did
NCT03009201 · OHSU Knight Cancer Institute
2017-03-10 – 2023-06-30 · Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
What this study did
NCT03056833 · Ronald Buckanovich
2017-06-10 – 2022-08-01 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
What this study did
NCT02780128 · Yael P Mosse
2016-07 – 2022-08 · Neuroblastoma, Cancer
What this study did
NCT03355794 · Children's Hospital Medical Center, Cincinnati
2017-11-14 – 2022-07-31 · Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma
What this study did
NCT03237390 · Mayo Clinic
2018-01-04 – 2022-05-17 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
What this study did
NCT03834740 · St. Joseph's Hospital and Medical Center, Phoenix
2019-01-19 – 2022-02-18 · Glioblastoma Multiforme, Glioma of Brain
What this study did
NCT02370706 · Novartis Pharmaceuticals
2015-05-21 – 2020-11-09 · Myelofibrosis
What this study did
NCT03387020 · Pediatric Brain Tumor Consortium
2018-01-13 – 2020-04-01 · CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Diffuse Intrinsic Pontine Glioma
What this study did
NCT02345824 · University of Virginia
2016-03 – 2020-01 · Glioblastoma, Glioma
What this study did
NCT02343172 · Novartis Pharmaceuticals
2015-03-13 – 2019-10-16 · Liposarcoma
What this study did
NCT02703571 · Novartis Pharmaceuticals
2016-06-29 – 2019-09-24 · Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
What this study did
NCT03179956 · Fox Chase Cancer Center
2018-04-02 – 2019-01-10 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02292550 · Novartis Pharmaceuticals
2015-05-14 – 2018-09-26 · Non-small Cell Lung Cancer
What this study did
NCT02429089 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2015-04 – 2018-09-01 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02431481 · Novartis Pharmaceuticals
2015-10-23 – 2018-05-11 · Normal Renal Function, Impaired Renal Function
What this study did
NCT01747876 · Novartis Pharmaceuticals
2013-05-28 – 2017-06-29 · Malignant Rhabdoid Tumors (MRT), Neuroblastoma
What this study did
NCT01237236 · Novartis Pharmaceuticals
2010-12-21 – 2017-03-09 · Advanced Solid Tumor, Lymphomas
What this study did
Phase 4 (7)
HR+/HER2- Metastatic Breast Cancer
NCT07630948 · Institute of Oncology Ljubljana
2026-09-01 – 2032-09-01 · Breast Cancer, Adherence, Medication
What this study did
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT05452213 · Institut fuer Frauengesundheit
2022-10-12 – 2026-10 · Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
What this study did
NCT07487129 · Beni-Suef University
2024-08-25 – 2025-12-20 · Breast Cancer
What this study did
NCT04657679 · Georgetown University
2021-05-20 – 2023-10-30 · Breast Cancer
What this study did
Other / comorbidity
NCT05691400 · University of Michigan Rogel Cancer Center
2024-03 – 2027-03 · CYP3A4*22
What this study did
Early phase / not applicable (4)
Breast Cancer
NCT06810492 · Hongmei Zheng, PhD
2025-04-01 – 2027-12-01 · Breast Cancer Stage III, Breast Cancer Stage II
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05244434 · City of Hope Medical Center
2022-07-03 – 2023-01-26 · Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Metastatic HER2-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
HR+/HER2- Metastatic Breast Cancer
NCT06757634 · Celcuity Inc
2025-07-24 – 2033-07-30 · Breast Cancer
What this study did
NCT06585969 · Danish Breast Cancer Cooperative Group
2026-01-01 – 2026-01-01 · Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like
What this study did
Phase 2 (2)
HR+/HER2- Metastatic Breast Cancer
NCT05766410 · National Taiwan University Hospital
2022-09-16 – 2026-09-30 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
What this study did
Early phase / not applicable (1)
HR+/HER2- Metastatic Breast Cancer
NCT07706933 · Henan Cancer Hospital
2026-11-01 – 2033-06-30 · Breast Cancer
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ribociclib: this drugApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
ZovegalisibPhase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
SPH4336Phase 2/3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
EvexomostatPhase 2Small moleculeMethionine aminopeptidase 2 (MetAP2, inhibitor)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 68 furthest-along competitors are listed; 37 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(59 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ribociclib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT02608216 · CT.gov ↗
What to watch
December 2026 (4)
Phase 2Soft Tissue SarcomaActive not recruiting
Est. primary completion 2026-12 · NCT03114527 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05870579 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06239467 · CT.gov ↗
What to watch
2027 (18)
January 2027 (1)
Phase 2Breast CancerEnrolling by invitation
Est. primary completion 2027-01-10 · NCT06481956 · CT.gov ↗
What to watch
February 2027 (4)
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT05996107 · CT.gov ↗
What to watch
Phase 2Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors …Active not recruiting
Est. primary completion 2027-02-01 · NCT02934568 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-02-02 · NCT04417621 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT05319873 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05216432 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06188520 · CT.gov ↗
What to watch
July 2027 (4)
Phase 1EGFR-mutant Non-small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-12 · NCT03333343 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07054190 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT04055493 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05683418 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT05508906 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT07380646 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT07195227 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT06062498 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma …Active not recruiting
Est. primary completion 2028-08-31 · NCT03008408 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-31 · NCT06377852 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09-25 · NCT06726148 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-11 · NCT06625775 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07618390 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07085767 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05816655 · CT.gov ↗
What to watch
2029 (12)
February 2029 (2)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07340658 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-02-28 · NCT07647328 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
July 2029 (2)
Phase 3Breast CancerRecruiting
Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗
What to watch
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma …Recruiting
Est. primary completion 2029-08-31 · NCT05843253 · CT.gov ↗
What to watch
September 2029 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-09-01 · NCT07164976 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-09-01 · NCT07630948 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2029-10-01 · NCT05296746 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-10-28 · NCT07767474 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (7)
February 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-02-10 · NCT07400523 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2030-05-29 · NCT03701334 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-10-01 · NCT07423611 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-06-30 · NCT06849947 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-11-30 · NCT07237256 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 November 2024ApprovalEuropean Commission approves Kisqali for HR+/HER2- early breast cancer
EU, EC · Source ↗